<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05117580</url>
  </required_header>
  <id_info>
    <org_study_id>TMED_METSZI_001</org_study_id>
    <nct_id>NCT05117580</nct_id>
  </id_info>
  <brief_title>Telemedicine With Metabolic Syndrome</brief_title>
  <acronym>METSZI</acronym>
  <official_title>Risk Reduction in Patients With Metabolic Syndrome Through Telemedicine-led Lifestyle Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Szeged University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Szeged University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of the effect of a 3-month telemedicine-led lifestyle intervention on&#xD;
      cardiovascular risk factors, functional indicators, in patients with metabolic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients are using mobile phone-based nutrition diary with heart rate monitoring watch&#xD;
      (including activity meter) connected to a mobile phone with bluetooth technology worn on a&#xD;
      wrist. These devices, and the weight scale, blood pressure monitor are connected with&#xD;
      bluetooth to an IT system, that transmits and displays data from these devices. the patients&#xD;
      are using the devices during 3 months, and get instructions about lifestyle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of abdominal circumference</measure>
    <time_frame>3 months</time_frame>
    <description>To investigate the effect of telemedicine-assisted lifestyle intervention on anthropometric parameters, with particular reference to the reduction of abdominal circumference in patients with metabolic syndrome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.</measure>
    <time_frame>3 months</time_frame>
    <description>The safety of the device system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the system to the cardiovascular risk</measure>
    <time_frame>3 months</time_frame>
    <description>In patients with metabolic syndrome, high cardiovascular risk, the impact of complex lifestyle interventions initiated in different environments and then telemedicine, including lifestyle and physical activity, on the known cardiovascular risk factors and functional indicators</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Life Style</condition>
  <arm_group>
    <arm_group_label>Active group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The active group get telemedicine devices, and lifestyle interventions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The comparator group get the evidence based treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>telemedicine lifestyle guidance</intervention_name>
    <description>Telemedicine lifestyle advices are given during 3 months, based on telemonitoring system data.</description>
    <arm_group_label>Active group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 years and 75 years&#xD;
&#xD;
          -  Presence of at least three of the following five risk factors (Metabolic Syndrome ATP&#xD;
             III Criteria):&#xD;
&#xD;
               1. waist width above 102 cm in men and 88 cm in women&#xD;
&#xD;
               2. treated diabetes or blood sugar above 5.6 mmol / l&#xD;
&#xD;
               3. treated hypertension or spontaneous blood pressure ≥ 130/85 mmHg&#xD;
&#xD;
               4. fibrate treatment or triglyceride levels above 1.7 mmol / l&#xD;
&#xD;
               5. blood HDL cholesterol levels below 1.03 mmol / l in men and 1.3 mmol / l in women&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Low level of physical activity (less than 30 minutes a day)&#xD;
&#xD;
          -  IT proficiency at least for basic use of mobile phones (answering / making voice&#xD;
             calls).&#xD;
&#xD;
          -  For women with childbearing potential, by definition, all women who are able to&#xD;
             conceive physiologically use dual contraception&#xD;
&#xD;
          -  Signing an informed consent.&#xD;
&#xD;
          -  The subject communicates well with the investigator and is able to help understand and&#xD;
             adhere to the requirements of the study plan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>István Kósa, MD, Ph.D.</last_name>
    <phone>+36 70 320 1192</phone>
    <email>office.prevmedicina@med.u-szeged.hu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>István Kósa, MD, Ph.D.</last_name>
      <phone>+36 70 320 1192</phone>
      <email>office.prevmedicina@med.u-szeged.hu</email>
    </contact>
    <investigator>
      <last_name>istván Kósa, MD Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Telemedicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

